Advances in Selegiline Therapy: The Role of Orally Disintegrating Tablets in Parkinson's Disease Management
Description
Selegiline is an irreversible monoamine oxidase-B (MAO-B) inhibitor primarily used in the management of Parkinson’s disease to enhance dopaminergic activity by inhibiting dopamine metabolism. The development of orally disintegrating tablet (ODT) or oral-mucosal formulations has significantly improved patient compliance, especially in individuals with dysphagia, while enhancing bioavailability and minimizing first-pass hepatic metabolism responsible for the formation of amphetamine-like metabolites. Clinical evidence supports selegiline’s role as an adjunct therapy to levodopa, improving motor symptoms and reducing “off” time in Parkinson’s disease. It may also provide modest symptomatic benefit in early-stage disease by delaying the need for levodopa initiation. However, its long-term neuroprotective or disease-modifying potential remains uncertain. The ODT formulation offers practical and pharmacokinetic advantages, but clinicians must remain vigilant regarding potential drug interactions—particularly with serotonergic or adrenergic agents as well as adverse effects such as insomnia, agitation, or hallucinations related to its amphetamine-derived metabolites.